474 related articles for article (PubMed ID: 20929607)
1. Current treatment of hereditary angioedema: An update on clinical studies.
Banerji A
Allergy Asthma Proc; 2010; 31(5):398-406. PubMed ID: 20929607
[TBL] [Abstract][Full Text] [Related]
2. Update on therapeutic developments for hereditary angioedema.
Christiansen SC; Zuraw BL
Allergy Asthma Proc; 2009; 30(5):500-5. PubMed ID: 19843404
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the management of hereditary angioedema.
Hemperly SE; Agarwal NS; Xu YY; Zhi YX; Craig TJ
J Am Osteopath Assoc; 2013 Jul; 113(7):546-55. PubMed ID: 23843378
[TBL] [Abstract][Full Text] [Related]
4. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
5. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12.
Bhattacharjee G; Revenko AS; Crosby JR; May C; Gao D; Zhao C; Monia BP; MacLeod AR
Nucleic Acid Ther; 2013 Jun; 23(3):175-87. PubMed ID: 23582057
[TBL] [Abstract][Full Text] [Related]
8. Progress in the emergency management of hereditary angioedema: focus on new treatment options in the United States.
Bernstein JA; Moellman JJ
Postgrad Med; 2012 May; 124(3):91-100. PubMed ID: 22691903
[TBL] [Abstract][Full Text] [Related]
9. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
Wu MA; Zanichelli A; Mansi M; Cicardi M
Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
[TBL] [Abstract][Full Text] [Related]
10. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
Moldovan D; Reshef A; Fabiani J; Kivity S; Toubi E; Shlesinger M; Triggiani M; Montinaro V; Cillari E; Realdi G; Cancian M; Visscher S; Zanichelli A; Relan A; Cicardi M
Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164
[TBL] [Abstract][Full Text] [Related]
13. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
14. The bradykinin-forming cascade and its role in hereditary angioedema.
Kaplan AP; Joseph K
Ann Allergy Asthma Immunol; 2010 Mar; 104(3):193-204. PubMed ID: 20377108
[TBL] [Abstract][Full Text] [Related]
15. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
[TBL] [Abstract][Full Text] [Related]
16. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
[TBL] [Abstract][Full Text] [Related]
17. Improving patient outcomes in hereditary angioedema: reducing attack frequency using routine prevention with C1 inhibitor concentrate.
Dominas N; Hoffmann TK; Bas M; Greve J
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24850548
[TBL] [Abstract][Full Text] [Related]
18. Management and prevention of hereditary angioedema attacks.
Lumry WR
Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
[TBL] [Abstract][Full Text] [Related]
19. Current drugs in early development for hereditary angioedema: potential for effective treatment.
Bork K
Expert Opin Investig Drugs; 2014 Jul; 23(7):887-91. PubMed ID: 24797354
[TBL] [Abstract][Full Text] [Related]
20. Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade.
Busse P; Kaplan A
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):716-722. PubMed ID: 34838707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
